Clinical Trials Browser

Phase 3 × Prostatic Neoplasms × Pioglitazone × Clear all

NCT05098327 2023-08-15

Pioglitazone and Insulin Resistance in ADT

Phase 3 Withdrawn

Diabetes Mellitus, Type 2, Insulin Resistance, Prostatic Neoplasms